NCT07354620

A Pilot Study on Reverse Aging (The REVERSE Study)

• Status: Active Not Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: The Christ Hospital · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Aging can be defined as a time-dependent functional decline in physiological function, which may increase the vulnerability to diseases and eventually death. The question is whether aging is a normal process, or exists as an "uber-illness?" Work done by Dr Sinclair at Harvard suggests the latter. Dr. Sinclair feels people should be able to age-in-place, or even reverse age. Aging is arguably the single biggest risk factor for all acquired and chronic diseases. Delaying the aging rate by 7 years would cut the incidence of chronic disease in half! Up until know the effects of anti-aging would need longitudinal studies until death. Now, with the advent of a 3rd generation OMIC Age clock, there is a way to assess if an intervention is changing the rate of aging and other methylation patterns associated with aging.

Conditions

• Aging

Interventions

Type	Name	Description
DRUG	Rapamycin (Tablets)	10 mg initial bolus dose of rapamycin followed by a weekly 6 mg rapamycin
DIETARY_SUPPLEMENT	Prolon diet	Prolon 5-day diet at 0, 1, 2, 3, 4,and 5 months

Timeline

• Start date: 2025-02-15
• Primary completion: 2026-02-01
• Completion: 2026-05-01
• First posted: 2026-01-21
• Last updated: 2026-01-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study